Neue molekulare Therapieoptionen, Sidedness, Kombinationen aus Chemotherapie mit EGFR/VEGF-Antikörper und TAS-102 Share: Do you want to read an article? Please log in or register. E mail Password Login Register for Free Remember me Forgot password? Click here
Do you want to read an article? Please log in or register. E mail Password Login Register for Free Remember me
